Where does Cerus Endovascular Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cerus Endovascular Limited ranks #31,172 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cerus Endovascular Limited hold?

Cerus Endovascular Limited holds 8 US utility patents granted between 2018 and 2023, spanning 2 technology areas.

What is Cerus Endovascular Limited's Innovation Score?

Cerus Endovascular Limited has an Innovation Score of 43.7 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cerus Endovascular Limited focus on?

Cerus Endovascular Limited's top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 8 patents, ranking #2,086 of 7,127 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Cerus Endovascular Limited's patent grant rate increasing or decreasing?

Cerus Endovascular Limited's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cerus Endovascular Limited's patents?

Cerus Endovascular Limited's patents average 18.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cerus Endovascular Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cerus Endovascular Limited

USPTO PatentsView assignee record - 8 granted patents across 2 technology areas, recorded in grant years 2018–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cerus ranks #31,172 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 2 technology areas.

#31,172
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.7/100): 18.5
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31172 · Foreign Corporation #31,172 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,172/49,997
PHOTO-FINISH Centurion Medical…
CPC-NARROW A61B · 2 areas
INNOV-PAR 43.7/100
CLAIMS-RICH 18.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Centurion Medical Products Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cerus’s 43.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (17%) Velocity 20.0 pts (46%) Breadth 5.0 pts (11%) Claim depth 11.1 pts (25%)

Qualcomm Incorporated · highest

85
Cerus Endovascular · this assignee

44
3D Lighting… · lowest

7

What this shows Cerus's Innovation Score is 43.7/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cerus?

Each dot is one of Cerus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cerus’s own 18.5 claims/patent is ABOVE the 18.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cerus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cerus's grants concentrate

Cerus Endovascular Limited is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2018. By volume, Cerus sits between Centurion Medical Products Corporation and Cheers Health, Inc..

Cerus's three-year grant acceleration

Cerus Endovascular Limited shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Centurion Medical…

8
Centurion VR

8
Cequint

8
Ceragon Networks

8
Chaos Software

8
Chargepoint Techn…

8
Charm Industrial

8
Cheers Health

8
Cerus Endovascular ◀

8

What this shows Cerus holds 8 patents at rank #31,269, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cerus

By rank, the assignees closest to #31,269 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Cerus's primary technology class.

Cerus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Cerus Endovascular Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	12.5%
2019	1	12.5%
2022	4	50.0%
2023	2	25.0%

Which technologies does Cerus Endovascular Limited patent most?

A61B - DIAGNOSIS; SURGERY; Identification 8

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cerus Endovascular Limited's patent record in context - here's where to go next.

Cerus Endovascular Limited's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #31,172 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cerus Endovascular Limited against Centurion Medical Products Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.